Tumor Necrosis Factor (TNF) Inhibitors 2018-2026: Global Market Size & Share, Application Analysis, Growth Trends, Key Players and Competitive Strategies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The “Global Tumor Necrosis Factor (TNF) Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026” report has been added to ResearchAndMarkets.com’s offering.
The tumor necrosis factor inhibitors market was valued at US$ 43.39 Bn in 2017 and expected to reach US$ 181.13 Bn by 2026, expanding at a CAGR of 16.5% from 2018 to 2026.
Only five approved TNF inhibitors dominate the current market namely, adalimumab, certolizumab, etanercept, golimumab and infliximab. The extensive application of these approved drugs for various autoimmune conditions ensures continuous market growth during the forecast period from 2018 to 2026.
Approval of biosimilars would further add to the lucrativeness of this market. Biosimilars will intensify the market competition in TNF inhibitors market as several industrial players are currently investing in their development.
High prevalence of chronic conditions such as Crohn’s disease, ulcerative colitis, plaque psoriasis, rheumatoid arthritis & others, continuous research activities in developing target-based biologics, provision of structured reimbursement policies and growing inclination towards cost-efficient biosimilars in developing economies contribute to the remunerative growth of this market.
Additionally, rising prevalence of chronic autoimmune disease such as Crohn’s disease, rheumatoid arthritis, plaque psoriasis and ulcerative colitis increase the need for target based therapies such as TNF inhibitors.
Key Market MovementsGlobally tumor necrosis factor inhibitors market witnesses a remunerative growth with a CAGR of 16.5 % during the forecast period from 2018 to 2026 Constant research activities in label expansion of TNF inhibitors enhancing its application across various disease areas thus catalyzing the market growth Rising prevalence of autoimmune disease across geographies and the use of TNF inhibitors for multiple autoimmune conditions catalyzing the market growth Biosimilars are expected to increase market competition in the near future and ensure incessant growth during the forecast period from 2018 to 2026
Key Topics Covered
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Global Tumor Necrosis Factor Inhibitors Market: Dynamics and Future Outlook
Chapter 4. Global Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
Chapter 5. Global Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
Chapter 6. Global Tumor Necrosis Factor Inhibitors Market, by Geography, 2016-2026 (US$ Mn)
Chapter 7. Profiles
7.1. Abbvie, Inc.
7.2. Amgen, Inc.
7.3. Biocad Biopharmaceutical Co.
7.4. Boehringer Ingelheim Pharmaceuticals, Inc.
7.5. EPIRUS Biopharmaceuticals, Inc.
7.6. Innovent Biologics, Inc.
7.7. Janssen Biotech, Inc.
7.8. Merck & Co., Inc.
7.9. Novartis A.G.
7.10. Pfizer, Inc.
7.11. Shanghai Henlius Biotech, Inc.
7.12. UCB S.A.
For more information about this report visit https://www.researchandmarkets.com/research/6kj9j4/tumor_necrosis?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180612006215/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/12/2018 12:59 PM/DISC: 06/12/2018 12:58 PM